Genmab revenues more than double year to date

3 November 2016

Denmark-based biotech firm Genmab (OMX: GEN) saw its shares jump 9.5% to 1,168.00 Danish kroner this morning, after it posted financial results showing sharply higher revenues and profits.

Genmab reported revenue of 889 million kroner in the first nine months of 2016 compared to 558 million kroner in the first nine months of 2015. The increase of 331 million kroner, or 59%, was mainly driven by higher royalty and milestone revenue under the daratumumab (trade name Darzalex) collaboration with Janssen.

Operating expenses were 544 million kroner, up 43% compared with the like 2015 period. The increase was due to the additional investment in our pipeline of products, including the advancement of tisotumab vedotin, HuMaxAXL-ADC, HexaBody-DR5/DR5, DuoBody-CD3xCD20, and the firm’s other pre-clinical programs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK